Search
for
Sort by
Research 61–90 of 1000+
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- 6ER-014 Evaluation of baricitinib in paediatric patients with alopecia areata
- Alopecia Universalis: Never Give Up?
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- 1368 Effects of phototherapy on refractory alopecia areata
- Deficiency Pattern and Responsiveness in Clinical Settings in Discovering the Correlation between Vitamin D Analogues and Hair Growth in Alopecia Areata
- Efficacy and safety of azathioprine in alopecia areata
- Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
- Study of effect of topical mometasone with intralesional platelet-rich plasma versus topical mometasone alone in the treatment of alopecia areata
- Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Response of alopecia areata of the beard to oral tofacitinib
- Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- A clinical study on alopecia areata